Enlivex Therapeutics Ltd. (ENLV) Income Statement
ENLV 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsENLV revenue and net income
ENLV profit margins
ENLV growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ENLV quarterly EPS vs estimates
Enlivex Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.28).
ENLV income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $2.3M | $0 | $0 | $0 | $0 |
| Cost of revenue | $332,000 | $545,000 | $835,000 | $777,000 | $546,000 | $286,000 | $297,000 | $121,000 | $12,000 | $25,000 |
| Gross profit | −$332,000 | −$545,000 | −$835,000 | −$777,000 | −$546,000 | −$286,000 | −$297,000 | −$121,000 | −$12,000 | −$25,000 |
| Research & development | $8.9M | $10.1M | $19.2M | $18.7M | $12.9M | $6.1M | $5.7M | $4.1M | $2.5M | $8.9M |
| Sales, general & admin | $5.7M | $4.9M | $6.1M | $6.7M | $6.2M | $3.6M | $2.8M | $937,000 | $3.0M | $7.0M |
| Total operating expenses | $14.7M | $15.0M | $29.4M | $25.8M | $19.3M | $9.8M | $8.6M | $5.2M | $5.8M | $13.9M |
| Operating income | −$15.0M | −$15.5M | −$29.4M | −$25.8M | −$19.3M | −$9.8M | −$8.6M | −$5.3M | −$5.8M | −$13.9M |
| Interest income | $792,000 | $1.1M | $1.6M | $835,000 | $120,000 | $225,000 | $238,000 | $138,000 | $39,000 | $90,000 |
| Interest expense | $13,000 | $13,000 | $14,000 | $5.3M | $328,000 | $6,000 | $7,000 | $3,000 | $0 | $0 |
| Income before taxes | $1.62B | −$15.0M | −$29.1M | −$31.1M | −$14.5M | −$11.8M | −$9.4M | −$4.2M | −$5.9M | −$15.8M |
| Income taxes | $382.6M | — | $4.2M | $11.3M | −$4.8M | $2.0M | $765,000 | $1.1M | $28,000 | $216,000 |
| Net income | $1.24B | −$15.0M | −$29.1M | −$31.1M | −$14.5M | −$11.8M | −$9.4M | −$4.2M | −$5.9M | −$16.0M |
| EBITDA | −$14.7M | −$14.5M | −$28.2M | −$25.0M | −$18.7M | −$9.5M | −$8.4M | −$5.2M | −$5.9M | −$13.9M |
| EPS (diluted) | −$6.21 | −$7.73 | −$18.25 | −$33.60 | −$0.79 | −$7.15 | −$0.81 | −$3.12 | −$13.12 | −$40.40 |
| Gross margin | — | — | — | — | — | −12.6% | — | — | — | — |
| Operating margin | — | — | — | — | — | −429.7% | — | — | — | — |
| Net margin | — | — | — | — | — | −519.3% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $57,000 | — | $76,000 | $81,000 | $85,000 | $90,000 | $36,000 | $161,000 | $160,000 | $188,000 | $200,000 | $214,000 |
| Gross profit | −$57,000 | — | −$76,000 | −$81,000 | −$85,000 | −$90,000 | −$36,000 | −$161,000 | −$160,000 | −$188,000 | −$200,000 | −$214,000 |
| Research & development | $2.9M | $3.3M | $3.0M | $1.5M | $2.1M | $2.5M | $3.4M | $2.3M | $2.0M | $2.9M | $4.5M | $4.3M |
| Sales, general & admin | $1.3M | $4.6M | $2.7M | $1.1M | $937,000 | $954,000 | $2.0M | $771,000 | $987,000 | $1.3M | $733,000 | $1.3M |
| Total operating expenses | $4.2M | $7.9M | $5.8M | $2.5M | $3.0M | $3.5M | $5.6M | $3.1M | $3.0M | $4.2M | $5.9M | $5.6M |
| Operating income | −$4.2M | −$7.9M | −$5.9M | −$2.6M | −$3.1M | −$3.5M | −$5.6M | −$3.1M | −$3.0M | −$4.0M | −$6.1M | −$5.6M |
| Interest expense | $1.3M | — | — | — | — | — | — | — | $110,000 | — | — | $335,000 |
| Income before taxes | $2.46B | $1.27B | $1.63B | −$2.2M | −$1.9M | −$3.5M | −$5.2M | −$2.6M | −$3.1M | −$4.1M | −$9.1M | −$6.0M |
| Income taxes | $566.7M | $293.6M | $382.6M | — | — | — | — | — | — | $144,724 | $156,188 | $253,586 |
| Net income | $1.89B | $974.5M | $1.24B | −$2.2M | −$1.9M | −$3.5M | −$5.2M | −$2.6M | −$3.1M | −$4.1M | −$9.1M | −$6.0M |
| EBITDA | −$4.2M | −$7.9M | −$5.8M | −$2.1M | −$3.0M | −$3.4M | −$5.1M | −$3.0M | −$2.8M | −$3.8M | −$5.9M | −$5.4M |
| EPS (diluted) | −$1.20 | −$0.15 | −$1.41 | −$1.35 | −$1.20 | −$2.25 | −$0.23 | −$1.80 | −$2.40 | −$3.30 | −$7.20 | −$4.80 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ENLV's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ENLV financial results
Enlivex Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had net income of $1.2 billion. Diluted earnings per share came to −$6.21.
See the ENLV stock overview for the latest quote and news, or the ENLV chart for price history and technical indicators.
ENLV income statement FAQ
Does Enlivex Therapeutics have revenue?
Enlivex Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Enlivex Therapeutics profitable?
Yes. Enlivex Therapeutics reported net income of $1.2 billion in fiscal 2025.
How much does Enlivex Therapeutics spend on research and development?
Enlivex Therapeutics spent $8.9 million on research and development in fiscal 2025.
What are Enlivex Therapeutics's earnings per share?
Enlivex Therapeutics earned $-6.21 per diluted share in fiscal 2025, compared with $-7.73 a year earlier.
When will Enlivex Therapeutics report its next earnings?
Enlivex Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Enlivex Therapeutics's fiscal year end?
Enlivex Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.